BACKGROUND: Thiazides and β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. METHODS: In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of dailyhydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. RESULTS: Increases in UA correlated with reductions in systolic BP (SBP) (r = -0.18; P = 0.003) and diastolic BP (DBP) (r = -0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = -0.27 and r = -0.21, respectively; both P < 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P < 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. CONCLUSIONS:BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.
RCT Entities:
BACKGROUND:Thiazides and β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. METHODS: In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of daily hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. RESULTS: Increases in UA correlated with reductions in systolic BP (SBP) (r = -0.18; P = 0.003) and diastolic BP (DBP) (r = -0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = -0.27 and r = -0.21, respectively; both P < 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P < 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. CONCLUSIONS: BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.
Authors: D Giugliano; R Acampora; R Marfella; N De Rosa; P Ziccardi; R Ragone; L De Angelis; F D'Onofrio Journal: Ann Intern Med Date: 1997-06-15 Impact factor: 25.391
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Steven M Smith; Shawn D Anderson; Sheron Wen; Yan Gong; Stephen T Turner; Rhonda M Cooper-Dehoff; Gary L Schwartz; Kent Bailey; Arlene Chapman; Karen L Hall; Hua Feng; Eric Boerwinkle; Julie A Johnson; John G Gums Journal: Pharmacotherapy Date: 2009-10 Impact factor: 4.705
Authors: Yan Gong; Caitrin W McDonough; Amber L Beitelshees; Jason H Karnes; Jeffrey R O'Connell; Stephen T Turner; Arlene B Chapman; John G Gums; Kent R Bailey; Eric Boerwinkle; Julie A Johnson; Rhonda M Cooper-DeHoff Journal: Pharmacotherapy Date: 2013-10-09 Impact factor: 4.705
Authors: Lakshmi Manasa S Chekka; Arlene B Chapman; John G Gums; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: Am J Med Date: 2021-01-09 Impact factor: 5.928
Authors: Ana Caroline C Sá; Amy Webb; Yan Gong; Caitrin W McDonough; Mohamed H Shahin; Somnath Datta; Taimour Y Langaee; Stephen T Turner; Amber L Beitelshees; Arlene B Chapman; Eric Boerwinkle; John G Gums; Steven E Scherer; Rhonda M Cooper-DeHoff; Wolfgang Sadee; Julie A Johnson Journal: BMC Med Genomics Date: 2018-06-20 Impact factor: 3.063
Authors: Ana Caroline C Sá; Amy Webb; Yan Gong; Caitrin W McDonough; Somnath Datta; Taimour Y Langaee; Stephen T Turner; Amber L Beitelshees; Arlene B Chapman; Eric Boerwinkle; John G Gums; Steven E Scherer; Rhonda M Cooper-DeHoff; Wolfgang Sadee; Julie A Johnson Journal: Sci Rep Date: 2017-11-22 Impact factor: 4.379